secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059333
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q1 revenue $367.7M (+52% YoY), net loss narrows to $0.56/share; achieves positive cash flow
--------------------------------------------------------------------------------

- Revenue $367.7M (+52.1% YoY); product revenue up 53.4%; gross margin 56.7% vs 38.7%.
- Net loss $67.6M ($0.56/share) vs $136.9M ($1.23/share) YoY; achieved ~$3M positive cash flow.
- Processed ~735,800 tests (+17.5%); oncology tests ~114,800 (+61.7%).
- Launched fetal RhD NIPT test; published key data in oncology and organ health.
- FY 2024 guidance: revenue $1.42B-$1.45B; gross margin 53-55%; net cash ($25M)-$25M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924059333/0001104659-24-059333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924059333/tm2413904d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer